An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory autoimmune disorders

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/91033/MonH-2022-348383(v2)
NMA SSA Reference Number: SSA/91033/MonH-2023-371351(v2)
Monash Health Local Reference: RES-22-0000-655A

StatusActive
Effective start/end date25/07/23 → 24/07/28